Shared on 12 Nov 25
ADMA: Buyback Activity And Margin Expansion Will Drive Robust Results
Analysts have increased their price target for ADMA Biologics to $27.25. They cite expectations for stronger revenue growth and higher profit margins, balanced against a slightly higher discount rate and declining future price-to-earnings multiples.
Shared on 29 Oct 25
Fair value Decreased 2.01%Analysts have slightly lowered their price target for ADMA Biologics from $27.81 to $27.25. They cited modest adjustments in financial assumptions, including revenue growth and profit margins.
Shared on 14 Oct 25
Fair value Decreased 4.30%Analysts have lowered their price target for ADMA Biologics from $29.06 to $27.81, primarily because of slight adjustments in fair value and future price-to-earnings estimates. Revenue growth and profit margin projections remain largely unchanged.
Shared on 30 Apr 25
Fair value Increased 0.40%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Fair value Increased 1.85%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 7.23%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Increased 1.57%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Decreased 1.24%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 11 Mar 25
Fair value Decreased 15%AnalystConsensusTarget has decreased shares outstanding growth rate from 0.0% to 0.0%.